Unlock instant, AI-driven research and patent intelligence for your innovation.

Car t-cell therapy directed to lhr for the treatment of solid tumors

Pending Publication Date: 2021-12-30
UNIV OF SOUTHERN CALIFORNIA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because of their ability to kill antigen expressing targets directly, CAR T-cells are highly toxic to any antigen positive cells or tissues making it a requirement to construct CARs with highly tumor specific antibodies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Car t-cell therapy directed to lhr for the treatment of solid tumors
  • Car t-cell therapy directed to lhr for the treatment of solid tumors
  • Car t-cell therapy directed to lhr for the treatment of solid tumors

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Mouse Anti-LHR Monoclonal Antibodies

[0279]Antibodies against the lysine rich extracellular hormone binding domain of LHR were generated by repeated immunization of 4 week-old-BALB / c and NIH Swiss mice with genetically engineered LHR-Fc. As shown below in FIG. 3, the leader sequence and first part of the human LHR G-protein was used to generate the LHR-Fc used in the immunization and screening methods to generate and identify high binding antibodies. Since flow cytometry has previously been shown to be the best predictor of functional antibodies for CAR generation, this method was used to identify potential candidate antibodies from over 7 fusions performed in the laboratory. A typical flow cytometry screen of hybridomas positive by initial ELISA screen using LHR-Fc coated plates is shown below in FIG. 4 using the ES-2 ovarian carcinoma cell line. As seen in this figure with hybridoma 8B7, only rare LHR hybridomas were shown to produce high MFI by flow cytometry. These few candi...

example 2

Monoclonal Antibodies Detecting the Expression of LHR in Ovarian Cancer

[0280]The overall hypothesis is that ovarian cancer can be treated effectively and safely with LHR chimeric antigen receptor modified T-cells. As a target, LHR has significant advantages over other targets due to its common expression on ovarian cancers and its lack of expression on normal human tissues. LHR CAR T-cells are produced in vitro and in vivo to identify a potential clinical candidate for subsequent clinical trials or use with dual targeting CAR modified T-cells.

Construction and Synthesis Single Chain LHR Antibody Genes

[0281]The DNA sequences for the 5 high binding anti-LHR antibodies (8B7-3, 5F4-21, 5B1-1, 2H11-37, and 138-2) were sequenced by MCLAB (South San Francisco, Calif.). All five antibodies are tested to determine which one produces the most effective CAR in assays described below. As shown below in FIG. 6, third generation CAR vectors were constructed consisting of the following tandem genes...

example 3

CAR T-Cells

Construction of the CAR Lentiviral Constructs

[0291]The CAR consists of an extracellular antigen binding moiety or scFV which binds LHR. The scFV is connected via a CD8 hinge region to the cytoplasmic signaling domain, comprised of the CD8 transmembrane region, and the signaling domains from CD28, 4-1BB and CD3z. The entire CAR sequence including the signaling domains, were synthetically synthesized by Genewiz Gene Synthesis Services (Piscataway, N.J.) (FIG. 10). The plasmids are purified and digested with the appropriate restriction enzymes to be inserted into an HIV-1-based, bicistronic lentiviral vector (pLVX-IRES-ZsGreen, Clontech, Signal Hill, Calif.) containing HIV-1 5′ and 3′ long terminal repeats (LTRs), packaging signal (Ψ), EF1α promoter, internal ribosome entry site (IRES), woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and simian virus 40 origin (SV40) via overnight T4 DNA ligase reaction (New England Biosciences; Ipswich, Mass.). Nov...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
binding constantaaaaaaaaaa
binding constantaaaaaaaaaa
binding constantaaaaaaaaaa
Login to View More

Abstract

Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 15 / 561,967, filed Sep. 26, 2017, which is a national stage entry under 35 U.S.C. § 371 of International Application No. PCT / US2016 / 024354, filed Mar. 25, 2016, which in turn claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62 / 139,623, filed Mar. 27, 2015, the content each of which are hereby incorporated by reference in their entirety.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 30, 2021, is named 116914-7160_SL.txt and is 77,010 bytes in size.TECHNICAL FIELD[0003]This disclosure relates to novel luteinizing hormone receptor (LHR) chimeric antigen receptor (CAR), cells or compositions comprising the same, and methods for using the same for therapy including solid tumors. Also ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28G01N33/574G01N33/76C07K16/30A61P35/00A61K35/17C07K14/725C07K14/705
CPCC07K16/2869A61K2035/124G01N33/57415G01N33/76C07K16/2809C07K16/3007A61P35/00A61K35/17C07K14/7051C07K14/70517C07K14/70578C07K16/3069G01N33/57449C07K2317/55G01N2800/52G01N33/57434A61K2039/5156A61K2039/5158C07K2319/03C07K2319/33C07K2317/622C07K2317/31C07K14/723C07K14/70521C07K2319/00C07K2319/02C07K2319/30A61K2039/505C07K2317/24C07K2317/54C07K2317/56C07K2317/565C07K2317/76
Inventor EPSTEIN, ALAN L.HU, PEISHENGPINSKI, JACEK K.
Owner UNIV OF SOUTHERN CALIFORNIA